Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report

Pediatric Neurology

Volumn 51, Issue 1, 2014, Pages 109-113

  Dill, Patricia E ^a,b   De Bernardis, Gaston ^a,b   Weber, Peter ^a   Lösch, Uli ^c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

facial angiofibromas; mTOR inhibitors; topical everolimus; tuberous sclerosis complex

Indexed keywords

ANTICONVULSIVE AGENT; EVEROLIMUS; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ANTICONVULSANT THERAPY; ARTICLE; CASE REPORT; CHILD; DRUG SAFETY; DRUG STRUCTURE; ECHOCARDIOGRAPHY; FACIAL ANGIOFIBROMA; FEMALE; HUMAN; INFANTILE SPASM; LOW LEVEL LASER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHABDOMYOMA; SCHOOL CHILD; SKIN DISEASE; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; ANALOGS AND DERIVATIVES; ANGIOFIBROMA; COMPLICATION; FACE; PATHOLOGY;

ANGIOFIBROMA; CHILD; FACE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TUBEROUS SCLEROSIS;

EID: 84902507788     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2014.02.016     Document Type: Article

References (29)

1. J.P. Osborne, A.C. Jones, and M.W. Burley et al. Non-penetrance in tuberous sclerosis Lancet 355 2000 1698
2. J. Huang, and B.D. Manning The TSC1-TSC2 complex: a molecular switchboard controlling cell growth Biochem J 412 2008 179 190
3. D.N. Franz, E. Belousova, and S. Sparagana et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 2012 125 132
4. J.J. Bissler, J.C. Kingswood, and E. Radzikowska et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Lancet 381 2013 817 824
5. FDA Drug Approval and Databases: Everolimus for Tuberous Sclerosis Complex (TSC). Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm317490.htm. Accessed September 24, 2013.
6. FDA Drug Approval and Databases: Everolimus 2012. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm302081.htm. Accessed September 24, 2013.
7. Swissmedic Prodcur Information Votubia. Available at: http://www.swissmedicinfo.ch. Accessed September 24, 2013.
8. M. Tanaka, M. Wataya-Kaneda, A. Nakamura, S. Matsumoto, and I. Katayama First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex Br J Dermatol 169 2013 1314 1318
9. J.W. Wheless, and H. Almoazen A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex J Child Neurol 28 2013 933 936
10. E. Kaufman McNamara, A.R. Curtis, and A.B. Fleischer Jr. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin J Dermatolog Treat 23 2012 46 48
11. M.K. Koenig, A.A. Hebert, and J. Roberson et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin Drugs R D 12 2012 121 126
12. T. Truchuelo, B. Díaz-Ley, L. Ríos, J. Alcántara, and P. Jaén Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response Dermatol Online J 18 2012 15
13. M. Wataya-Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto, and I. Katayama A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex Arch Dermatol 148 2012 138 139
14. C.M. DeKlotz, A.E. Ogram, S. Singh, S. Dronavalli, and J.L. MacGregor Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol Arch Dermatol 147 2011 1116 1117
15. R.S. Foster, L.J. Bint, and A.R. Halbert Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients Australas J Dermatol 53 2012 52 56
16. M.M. Mutizwa, D.R. Berk, and M.J. Anadkat Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis Br J Dermatol 165 2011 922 923
17. R. Salido, G. Garnacho-Saucedo, and I. Cuevas-Asencio et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma J Eur Acad Dermatol Venereol 26 2012 1315 1318
18. M. Wataya-Kaneda, M. Tanaka, A. Nakamura, S. Matsumoto, and I. Katayama A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity Br J Dermatol 165 2011 912 916
19. A.K. Haemel, A.L. O'Brian, and J.M. Teng Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis Arch Dermatol 146 2010 715 718
20. Guido Büch Entwicklung von Arzneiformen zur dermalen und ophthalmologischen Applikation schwerlöslicher Immunsuppressiva Dissertation 2007 Freie Universität Berlin, Germany
21. Yuri V. Il'ichev, Lori Alquier, and Cynthia A. Maryanoff Degradation of rapamycin and its ring-opened isomer: role of base catalysis ARKTVOC 2007 110 131
22. H.E. Junginger, and H.E. und Bodde Gel structures of dermatological vehicles and their influence on drug release Top. Pharm. Sci. Proc Int Congr Pharm Sci FIP 45 1985 329 343
23. Walther Kern, Theodor Cordes, Untersuchungen über Handelsvaselinen, Article first published online: 23 Sep 2006, http://dx.doi.org/10.1002/ardp. 19432810104.
24. A.A. Gomes, Y.V. Gomes, F.B. Lima, and S.G. Pessoa Multiple facial angiofibromas treated with high-frequency equipment An Bras Dermatol 86 4 Suppl 1 2011 S186 S189
25. E.T. Weiss, and R.G. Geronemus New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis Lasers Surg Med 42 2010 357 360
26. P. Boixeda, E. Sánchez-Miralles, J.M. Azaña, J.M. Arrazola, R. Moreno, and A. Ledo CO2, argon, and pulsed dye laser treatment of angiofibromas J Dermatol Surg Oncol 20 1994 808 812
27. C.H. Weinberger, B. Endrizzi, K.P. Hook, and P.K. Lee Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser Dermatol Surg 35 2009 1849 1851
28. Y.S. Bae-Harboe, and R.G. Geronemus Targeted topical and combination laser surgery for the treatment of angiofibromas Lasers Surg Med 45 2013 555 557
29. J. Park, S.K. Yun, Y.S. Cho, K.H. Song, and H.U. Kim Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy Dermatology 228 2014 37 41